DNA sequencing: the end of a near-monopoly

For the last decade, the field of DNA sequencing has been dominated by a single company, Illumina, with very limited competition. However, a new method with superior performance and lower cost has recently been announced by Roche, a major pharmaceutical and diagnostics company, and promises to have...

Full description

Saved in:

Bibliographic Details
Published in	M.S. Médecine sciences Vol. 41; no. 6-7; p. 611
Main Author	Jordan, Bertrand
Format	Journal Article
Language	French
Published	France 01.06.2025
Subjects	Commerce High-Throughput Nucleotide Sequencing - economics High-Throughput Nucleotide Sequencing - methods High-Throughput Nucleotide Sequencing - trends Humans Sequence Analysis, DNA - economics Sequence Analysis, DNA - instrumentation Sequence Analysis, DNA - methods Sequence Analysis, DNA - trends
Online Access	Get full text
ISSN	1958-5381 1958-5381
DOI	10.1051/medsci/2025097

Cover

More Information
Summary:	For the last decade, the field of DNA sequencing has been dominated by a single company, Illumina, with very limited competition. However, a new method with superior performance and lower cost has recently been announced by Roche, a major pharmaceutical and diagnostics company, and promises to have a large impact, especially (but not exclusively) for medical applications.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-News-4
ISSN:	1958-5381 1958-5381
DOI:	10.1051/medsci/2025097